The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2015

Filed:

Jul. 25, 2013
Applicants:

Trustees of Tufts College, Boston, MA (US);

New England Medical Center Hospitals, Inc., Boston, MA (US);

1149336 Ontario, Inc., Toronto, CA;

Inventors:

William W. Bachovchin, Cambridge, MA (US);

Andrew G. Plaut, Lexington, MA (US);

Daniel J. Drucker, Toronto, CA;

Assignees:

1149336 Ontario, Inc., Toronto, Ontario, CA;

New England Medical Center Hospitals. Inc., Boston, MA (US);

Trustees of Tufts College, Boston, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/02 (2006.01); A61K 38/05 (2006.01); A61K 38/55 (2006.01); A61K 31/00 (2006.01); A61K 31/155 (2006.01); A61K 31/401 (2006.01); A61K 31/4025 (2006.01); A61K 31/675 (2006.01); A61K 31/69 (2006.01); A61K 31/702 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/05 (2013.10); A61K 31/00 (2013.01); A61K 31/155 (2013.01); A61K 31/401 (2013.01); A61K 31/4025 (2013.01); A61K 31/675 (2013.01); A61K 31/69 (2013.01); A61K 31/702 (2013.01); A61K 38/55 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention provides methods for modification and regulation of glucose metabolism by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to increase the plasma half-life of glucagon-like peptide 1 (GLP-1) but not sufficient to suppress the immune system of the animal.


Find Patent Forward Citations

Loading…